Drugs / Riabni
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | RIABNI | — | 2022-06-03 | fda.gov ↗ |
| Approved | US (FDA) | RIABNI | — | 2020-12-17 | fda.gov ↗ |
Trials 0
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07634471 Background | Jun 2026 → Jul 2032 expected | follicular lymphoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05624554 Comparator | Mar 2023 → May 2027 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RIABNI | “RIABNI®” NCT07634471 ↗ |
| Route | Intravenous | “Administered as an IV infusion” NCT05624554 ↗ |